Surveillance study examined the safety of brentuximab vedotin in Japanese patients with relpased Hodgkin or ALCL lymphomas.
Home / Resource Library / Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study